Aurinia Pharmaceuticals (AUPH) Accounts Payables (2016 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Accounts Payables data on file, last reported at $2.7 million in Q1 2026.

• Quarterly Accounts Payables fell 36.94% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 36.94% YoY) and the FY2025 annual result came in at $3.3 million, down 36.13% from the prior year.
• Accounts Payables eased to $2.7 million in Q1 2026, from $3.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $56.8 million in Q3 2024 to a low of $2.2 million in Q3 2025.
• A 5-year average of $27.2 million and a median of $32.4 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables soared 82.7% — and 2025, when it slumped 96.1%.
• Tracing AUPH's Accounts Payables over 5 years: stood at $40.0 million in 2022, then plunged by 89.18% to $4.3 million in 2023, then gained by 19.88% to $5.2 million in 2024, then plunged by 36.13% to $3.3 million in 2025, then decreased by 19.68% to $2.7 million in 2026.
• The last three Accounts Payables figures came in at $2.7 million (Q1 2026), $3.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.